Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer - Top-Institutions - MDSpire

Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer

  • By

  • Xiangyuan Zhou

  • Xianming Huang

  • Lan Liu

  • Xiaoqin Cai

  • Han Li

  • Zhikang Sun

  • Zongqing Qiu

  • Jinxiu Zhong

  • Tenghua Yu

  • Qiao Zeng

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    GARNET trial
    GARNET trial

    N/A, N/A

    Key Differentiators

    • Oncology

  • #2

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Oncology

  • #4

    Gustave Roussy
    Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Oncology

Original Source(s)

Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer

  • by Xiangyuan Zhou, Xianming Huang, Lan Liu, Xiaoqin Cai, Han Li, Zhikang Sun, Zongqing Qiu, Jinxiu Zhong, Tenghua Yu, Qiao Zeng

  • June 10, 2026

Related Content

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

A multimodal ultrasound-based model combining tumor radiomics and axillary lymph node morphologic classification for predicting axillary nodal burden in breast cancer

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib